Everolimus-Eluting Bioresorbable Scaffolds and Metallic Stents in Diabetic Patients: a Patient-level Pooled Analysis of the Prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS

T. M. Hommels (✉ Tobiashommels@gmail.com)
Isala  https://orcid.org/0000-0002-8527-6254

R. S. Hermanides
Isala

B. Berta
Isala

E. Fabris
Universita degli Studi di Trieste Dipartimento di Scienze Mediche e Chirurgiche e della Salute

G. De Luca
Azienda Ospedaliero-Universitaria Maggiore della Carita

E. H. Ploumen
Medisch Spectrum Twente

C. von Birgelen
Medisch Spectrum Twente

E. Kedhi
AZ Sint-Jan Brugge-Oostende AV

Original investigation

Keywords: Bioresorbable scaffolds, Drug-eluting stents, Diabetes mellitus, Coronary artery disease, Percutaneous coronary intervention, Device thrombosis

DOI: https://doi.org/10.21203/rs.3.rs-37481/v1

License: ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background**: Several studies compared everolimus-eluting bioresorbable scaffolds (EE-BRS) with everolimus-eluting stents (EES), but only few assessed these devices in patients with diabetes mellitus.

**Aim**: To evaluate the safety and efficacy outcomes of all-comer patients with diabetes up to 2 years after treatment with EE-BRS or EES.

**Methods**: We performed a post-hoc pooled analysis of patient-level data in diabetic patients who were treated with EE-BRS or EES in 3 prospective clinical trials: The ABSORB DM Benelux Study (NTR5447), TWENTE (NTR1256/NCT01066650) and DUTCH PEERS (NTR2413/NCT01331707). Primary endpoint of the analysis was target lesion failure (TLF): a composite of cardiac death, target vessel myocardial infarction or clinically driven target lesion revascularization. Secondary endpoints included major adverse cardiac events (MACE): a composite of all-cause death, any myocardial infarction or clinically driven target vessel revascularization, as well as definite or probable device thrombosis (ST).

**Results**: A total of 499 diabetic patients were assessed, of whom 150 received EE-BRS and 249 received EES. Total available follow-up was 222.6 patient years (PY) in EE-BRS and 464.9 PY in EES. The adverse events rates were similar in both treatment groups for TLF (7.2 vs. 5.2 events per 100 PY, p=0.39; adjusted hazard ratio (HR)=1.48 (95% confidence interval (CI): 0.77-2.87), p=0.24), MACE (9.1 vs. 8.3 per 100 PY, p=0.83; adjusted HR=1.23 (95% CI: 0.70-2.17), p=0.47), and ST (0.9 vs. 0.6 per 100 PY, p>0.99).

**Conclusion**: In this patient-level pooled analysis of patients with diabetes mellitus from 3 clinical trials, EE-BRS showed clinical outcomes that were quite similar to EES.

Background

Diabetes mellitus is a well-established predictor of adverse clinical and angiographic events following percutaneous coronary intervention (PCI) with metallic drug-eluting stents (DES) for obstructive coronary artery disease (CAD) (1–6). Various disease-related factors contribute to a pro-inflammatory and pro-thrombotic state and reduce the prognosis of patients with diabetes, such as endothelial dysfunction, changes in plaque composition, platelet activation and coagulation disturbances (7). Following PCI with stent implantation, the aforementioned mechanisms may be even aggravated by the permanent presence of the metallic vascular prosthesis that mechanically distorts the arterial geometry, delays vascular healing and constrains vascular response in the treated coronary segment (8–10).

The everolimus-eluting bioresorbable scaffolds (EE-BRS) were developed to overcome some shortcomings of the metallic DES (11, 12). Because of its resorbable nature and its transient presence after implantation, it was hypothesized that EE-BRS may be associated with a more favorable restoration of the treated coronary vessel and a more favorable long-term clinical outcome. In addition, the use of EE-BRS may allow for repeating PCI in the same target lesion without loss of lumen size due to the lifelong presence of multiple layers of metallic stents in the coronary vessel. Furthermore, it is likely to facilitate
coronary artery bypass grafting (CABG) that may be required at a later point in time. Consequently, patients with diabetes, who are known to have an increased risk of repeated PCI and finally surgical treatment with CABG, may show a particular benefit from PCI with the utilization of EE-BRS.

Nevertheless, data from studies that compare EE-BRS and DES in an all-diabetic patient population are scarce. For that reason, we pooled patient-level data from 3 prospective clinical trials to compare the clinical outcome after PCI with EE-BRS and everolimus-eluting stents (EES) in all-comers with diabetes.

**Methods**

**Study population**

For the purpose of this analysis we pooled data of all patients with diabetes, who were treated with EE-BRS in de novo coronary lesions in the prospective ABSORB DM Benelux Study or who underwent PCI with EES for obstructive CAD in the TWENTE and DUTCH PEERS trials. The design and outcomes of the individual studies have been reported previously (13–16). The ABSORB DM Benelux Study is a prospective, international observational study in all-comer patients with diabetes who underwent PCI with EE-BRS. The TWENTE study is a Dutch randomized trial that examined the performance of second-generation EES to zotarolimus-eluting stents in all-comers. DUTCH PEERS is a Dutch multicenter randomized trial that assessed the performance of new-generation EES to zotarolimus-eluting stents in an all-comer population. All available follow-up data up to 2 years after PCI was used.

**Percutaneous coronary intervention procedure**

Implanted EE-BRS devices were the bioresorbable polymer drug-eluting scaffold ABSORB BVS system and the ABSORB GT1 system (Abbott Vascular, Santa Clara, CA, USA). Both devices are composed of poly-L-lactic acid with a strut thickness of 150 µm, covered by a polymer coating of poly-DL-lactic-acid that elutes everolimus. EE-BRS are expected to be completely resorbed within 3 years (12). The available scaffold diameters ranged from 2.50–3.50 mm with lengths of 8–28 mm. The durable fluoropolymer-coated Xience V EES (Abbott Vascular, Santa Clara, CA, USA) is a cobalt-chromium EES with a strut thickness of 81 µm; it was available in diameters from 2.25-4.00 mm with lengths of 8–28 mm. The strut thickness, polymer coating, eluted drug and available stent diameters of the platinum-chromium-based EES (Promus Element, Boston Scientific, Natick, MA, USA) were the same as for Xience V EES; the available stent length ranged from of 8–38 mm.

Angiographic success was defined as a < 50% residual stenosis of the target lesion after successful device implantation, as visually assessed. Procedural success was defined as angiographic success without occurrence of any adverse cardiac event during index hospitalization. In general, dual antiplatelet therapy (DAPT) was prescribed for 12 months after PCI, reflecting contemporary international guideline recommendations.

**Study endpoints**
The primary device-oriented endpoint of target lesion failure (TLF) is a composite of cardiac death, target vessel myocardial infarction (TV-MI) or clinically driven target lesion revascularization (TLR). Secondary endpoints include the patient-oriented endpoint of major adverse cardiac events (MACE), which is defined as a composite of all-cause death, any myocardial infarction (MI) or clinically driven target vessel revascularization (TVR), as well as definite or probable device (i.e., scaffold or stent) thrombosis (ST). All endpoints were defined according to clinical data standards of the American College of Cardiology/American Heart Association and the Academic Research Consortium (17–20).

**Statistical analysis**

Categorical variables are presented as frequencies and percentages. A 2-sided Pearson's Chi-square test was performed to determine significant differences between the EE-BRS and EES groups. The Fisher's exact test was used if appropriate due to small sample sizes with low frequency variables. Continuous variables with normal distribution are presented as mean and standard deviation, and a 2-sided independent student t-test was used to compare groups. An equal variance was upheld unless a significant Levene's test had been calculated; in that case a t-test with unequal variances was conducted. The clinical outcomes of the composite endpoints TLF and MACE were obtained by means of Kaplan-Meier survival methods with time-to-event analysis in addition to a log-rank test at 2-year follow-up. To adjust for variable time to follow-up between trials, all endpoints and the composites of TLF and MACE are presented in event rates per 100 patient years (PY) with the Poisson distribution given with 95% confidence interval (CI). In addition, a multivariate Cox regression model with adjustment for age, insulin-treated diabetes, number of treated vessels, total treated vessel length and treatment group was built for both TLF and MACE, reported as hazard ratio (HR) and 95% CI. P-values < 0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 25 (IBM Corp., Armonk, NY, USA).
Table 1

| Baseline clinical characteristic | EE-BRS (n = 150) | EES (n = 249) | p-value |
|----------------------------------|------------------|---------------|---------|
| Age (years) - mean ± SD          | 64.3 ± 10.1      | 67.1 ± 10.2   | < 0.01  |
| Sex (male) - no.(%)              | 108 (72.0)       | 159 (63.9)    | 0.09    |
| Body-mass index (kg/m²) - mean ± SD; no. | 29.5 ± 5.1, 148* | 29.3 ± 4.8, 221* | 0.63    |
| Risk factors - no.(%)            |                  |               |         |
| Insulin-treated diabetes         | 52 (34.7)        | 163 (34.5)    | 0.98    |
| Arterial hypertension            | 104 (69.3)       | 176 (70.7)    | 0.78    |
| Hypercholesterolemia             | 100 (66.7)       | 157 (63.1)    | 0.47    |
| Family history of cardiovascular disease | 59 (39.3)   | 131 (52.6)    | 0.01    |
| Current smoker                   | 35 (23.3)        | 50 (20.1)     | 0.44    |
| Medical history - no.(%)         |                  |               |         |
| Previous acute coronary syndrome  | 28 (18.7)        | 59 (23.7)     | 0.24    |
| Previous PCI                     | 37 (24.7)        | 54 (21.7)     | 0.49    |
| Previous CABG                    | 8 (5.3)          | 24 (9.6)      | 0.13    |
| Chronic renal failure**          | 6 (4.0)          | 12 (4.8)      | 0.70    |
| Clinical presentation - no.(%)   |                  |               |         |
| Acute coronary syndrome          | 73 (48.7)        | 120 (48.2)    | 0.93    |
| Myocardial infarction            | 47 (31.3)        | 74 (29.7)     | 0.73    |
| Unstable angina pectoris         | 26 (17.3)        | 46 (18.5)     | 0.77    |
| Non-acute coronary syndrome      | 77 (51.3)        | 129 (51.8)    | 0.93    |

Shown are the clinical characteristics at baseline for both patient groups. Plus - minus values are means ± standard deviation (SD) and the number in italic* represent the known total of which the variable was calculated. ** Renal insufficiency was defined as serum creatinine level of ≥130 µmol per liter. A p-value < 0.05 was considered as statistically significant.

Abbreviations: EE-BRS = everolimus-eluting bioresorbable scaffolds, EES = everolimus-eluting stents, PCI = percutaneous coronary intervention, CABG = coronary artery bypass grafting.

Results
Patient-level data were available from 499 diabetic patients; 150 patients (188 target lesions) were treated with EE-BRS and 249 (336 target lesions) with EES. Baseline clinical characteristics of both patient groups are shown in Table 1. Patients treated with EE-BRS were younger and had less frequently a family history of cardiovascular disease. Other baseline characteristics, including most details of the medical history, the prescription of insulin and the clinical presentation at the time of the index PCI did not differ between groups.

The angiographic characteristics are presented in Table 2. There was no significant difference in the distribution of the target vessels, except for left main stem treatment which was only performed in a few EES-treated patients. In the EE-BRS group, a few patients with CABG treatment were included. Although the number of target lesions per patient was similar in both groups, the EES group had a greater number of treated vessels, which resulted in a longer total device length. In addition, the EES group underwent more often bifurcation treatment. Nevertheless, both treatment groups showed similar angiographic and procedural results.

Follow-up was available for all but 3 patients who were lost to follow-up. Total available follow-up was 222.6 PY for EE-BRS and 464.9 PY for EES. Clinical outcomes are reported in Table 3 and Figs. 1 and 2. In all clinical endpoints, there was no significant difference between EE-BRS and EES. TLF event rates were 7.2 vs. 5.2 events per 100 PY (p = 0.39) (adjusted HR 1.48, 95% CI: 0.77–2.87; p = 0.24). The rates of MACE were 9.1 vs. 8.3 events per 100 PY (p = 0.83) (adjusted HR 1.23, 95% CI: 0.70–2.17; p = 0.47). No significant difference was observed in any individual component of these composite endpoints. ST rates were 0.9 vs. 0.6 per 100 PY (p > 0.99). Table 4 present the results of the multivariate Cox regression model for TLF and MACE. After correction for age, insulin-treated diabetes, multiple vessel treatment and total treated length, we found again no significant difference between EE-BRS and EES. Nevertheless, multivariable analysis revealed borderline non-significant relations between insulin-treatment and TLF (p = 0.06) and between patient age and MACE (p = 0.06).
Table 2
Angiographic characteristics of the patients at baseline

| Baseline angiographic characteristic                      | EE-BRS | EES    | p-value |
|-----------------------------------------------------------|--------|--------|---------|
| Patient-level analysis                                    |        |        |         |
| Number of patients                                       | 150    | 249    |         |
| Number of treated vessels - mean ± SD                    | 1.1 ± 0.3 | 1.2 ± 0.4 | < 0.01 |
| Number of treated target lesions - mean ± SD             | 1.3 ± 0.5 | 1.3 ± 0.6 | 0.22   |
| Total number of devices - mean ± SD                      | 1.4 ± 0.7 | 1.8 ± 1.1 | < 0.01 |
| Lesion-level analysis                                     |        |        |         |
| Number of lesions                                        | 188    | 336    |         |
| Coronary artery lesion distribution - no.(%)              |        |        |         |
| Right coronary artery                                    | 57 (30.3) | 108 (32.1) | 0.67   |
| Left anterior descending artery                           | 89 (47.6) | 144 (42.9) | 0.42   |
| Circumflex artery                                        | 40 (21.3) | 82 (24.4) | 0.30   |
| Left main                                                | 0 (0)  | 10 (3.0) | 0.02   |
| Arterial or venous graft                                  | 2 (1.1) | 0      | 0.13   |
| Coronary artery lesion characteristics                    |        |        |         |
| Bifurcation or trifurcation - no.(%)                      | 27 (14.4) | 77 (22.9) | 0.02   |
| Device-level analysis                                     |        |        |         |
| Number of devices                                        | 214    | 454    |         |
| Diameter device - mean ± SD                              | 3.0 ± 0.4 | 2.9 ± 0.5 | < 0.01 |
| Highest device inflation - mean ± SD; no.¶               | 14.3 ± 2.6, 211* | 15.4 ± 4.3, 446* | < 0.01 |
| Total length of devices per lesion - mean ± SD            | 23.7 ± 11.7 | 27.0 ± 15.4 | < 0.01 |
| Procedure-level analysis                                 |        |        |         |
| Number of PCI procedures                                 | 188    | 336    |         |
| Results - no.(%)                                          |        |        |         |
| Post-procedural TIMI grade 3                              | 186 (100), 186* | 334 (99.4) | 0.54   |
| Angiographic success                                      | 185 (100), 185* | 334 (99.4) | 0.54   |
| Procedural success                                        | 184 (97.9) | 327 (97.3) | 0.70   |
| Peri-implantation procedures                              |        |        |         |
| Baseline angiographic characteristic               | EE-BRS        | EES          | p-value |
|--------------------------------------------------|---------------|--------------|---------|
| Predilatation - no. (%)                          | 177 (94.1)    | 227 (67.6)   | < 0.01 |
| Predilatation balloon size - mean ± SD; no.[I]   | 2.8 ± 0.8, 176*| 2.4 ± 0.5    | < 0.01 |
| Predilatation pressure - mean ± SD; no.¶        | 14.8 ± 4.0, 174*| 14.5 ± 4.5  | 0.51   |
| Postdilatation - no. (%)                         | 142 (75.5)    | 273 (81.3)   | 0.12   |
| Postdilatation balloon size - mean ± SD¶        | 3.2 ± 0.5     | 3.1 ± 0.5    | 0.34   |
| Postdilatation pressure - mean ± SD¶            | 17.3 ± 4.3    | 22.5 ± 5.5   | < 0.01 |

Shown are the angiographic characteristics for both patient groups. Plus - minus values are means ± standard deviation (SD) and the numbers in italic* represent the known total of which the variable was calculated. † Length of lesions, devices and balloons were measured in millimeter (mm) as was the diameter of the devices. ¶ Dilatation and inflation pressures were measured in atmosphere (atm). A p-value < 0.05 was considered as statistically significant.

Abbreviations: EE-BRS = everolimus-eluting bioresorbable scaffolds, EES = everolimus-eluting stents, PCI = percutaneous coronary intervention, TIMI = Thrombolysis in Myocardial Infarction with grade 3 referenced as completely restored flow.

Discussion

This analysis of pooled patient-level data, comparing EE-BRS with EES for treatment of CAD in patients with diabetes, showed similar event rates in both treatment groups for the device-oriented and the patient-oriented composite endpoint. Importantly, safety outcomes were also similar, including cardiac death and TV-MI. A multivariable analysis for the composite clinical endpoints TLF and MACE confirmed the absence of a significant difference between both groups.
Table 3
Safety and efficacy outcomes at follow-up

| Endpoints and clinical events | EE-BRS (n = 147) | EES (n = 249) | p-value log rank | p-value PY event rate |
|------------------------------|------------------|---------------|------------------|----------------------|
|                              | % (n) KM         | 100 PY (95% CI) | % (n) KM         | 100 PY (95% CI)       |
| TLF*                         | 11.7 (16)        | 7.2 (4.1–11.7)  | 9.7 (24)         | 5.2 (3.3–7.7)         | 0.40   | 0.39   |
| Cardiac death                | 3.4 (5)          | 2.1 (0.7–5.0)   | 4.4 (11)         | 2.3 (1.1–4.1)         | 0.84   | > 0.99 |
| TV-MI                         | 3.6 (5)          | 2.2 (0.7–5.1)   | 2.8 (7)          | 1.5 (0.6–3.1)         | 0.69   | 0.69   |
| TLR                          | 5.5 (7)          | 3.1 (1.2–6.3)   | 3.3 (8)          | 1.7 (0.7–3.3)         | 0.23   | 0.36   |
| MACE**                       | 15.2 (20)        | 9.1 (5.6–14.1)  | 15.3 (38)        | 8.3 (5.9–11.4)        | 0.75   | 0.83   |
| All-cause death              | 3.4 (5)          | 2.1 (0.7–5.0)   | 6.8 (17)         | 3.5 (2.1–5.6)         | 0.35   | 0.45   |
| Any MI                       | 4.9 (7)          | 3.1 (1.3–6.4)   | 3.2 (8)          | 1.7 (0.7–3.3)         | 0.40   | 0.36   |
| TVR                          | 9.3 (11)         | 4.9 (2.5–8.8)   | 6.6 (16)         | 3.4 (2.0–5.5)         | 0.29   | 0.46   |
| ST†                          | 1.4 (2)          | 0.9 (0.1–3.1)   | 1.2 (3)          | 0.6 (0.1–1.8)         | 0.90   | > 0.99 |
| Early                        | (2)              | (2)            |                  |                      |        |        |
| Acute                        | (0)              | (2)            |                  |                      |        |        |
| Subacute                     | (2)              | (0)            |                  |                      |        |        |

Shown are the clinical outcomes represented as endpoints and clinical events. Three patients were lost to follow-up in the everolimus-eluting bioresorbable scaffolds group. The results are presented by 2-year Kaplan-Meier estimates and are also reported in event rates per 100 patient years with 95% confidence intervals to adjust for the variable time to follow-up between both groups. A p-value < 0.05 was considered as statistically significant; no significant differences were found between both treatment groups at follow-up. * Target lesion failure was defined as a composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularization. ** Major adverse cardiac events were defined as a composite of all-cause death, any myocardial infarction and clinically driven target vessel revascularization. † Device thrombosis was defined as early if observed between 0–30 days after index procedure, including a further distinction between acute ≤ 24 hours and subacute > 1–30 days. Device thrombosis was defined as late if ≤ 1 year and as very late if > 1 year. Abbreviations: EE-BRS = everolimus-eluting bioresorbable scaffolds, EES = everolimus-eluting stents, PY = patient years, KM = Kaplan-Meier, CI = confidence interval, TLF = target lesion failure, TV-MI = target vessel myocardial infarction, TLR = target lesion revascularization, MACE = major adverse cardiac events, MI = myocardial infarction, TVR = target vessel revascularization, ST = device thrombosis.
| Endpoints and clinical events | EE-BRS (n = 147) | EES (n = 249) | p-value log rank | p-value PY event rate |
|------------------------------|------------------|---------------|-----------------|---------------------|
| Late                         | (0)              | (1)           |                 |                     |
| Very late                    | (0)              | (0)           |                 |                     |
| Definite                     | (1)              | (1)           |                 |                     |
| Probable                     | (1)              | (2)           |                 |                     |

Shown are the clinical outcomes represented as endpoints and clinical events. Three patients were lost to follow-up in the everolimus-eluting bioresorbable scaffolds group. The results are presented by 2-year Kaplan-Meier estimates and are also reported in event rates per 100 patient years with 95% confidence intervals to adjust for the variable time to follow-up between both groups. A p-value < 0.05 was considered as statistically significant; no significant differences were found between both treatment groups at follow-up. * Target lesion failure was defined as a composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularization. ** Major adverse cardiac events were defined as a composite of all-cause death, any myocardial infarction and clinically driven target vessel revascularization. Device thrombosis was defined as early if observed between 0–30 days after index procedure, including a further distinction between acute ≤ 24 hours and subacute > 1–30 days. Device thrombosis was defined as late if ≤ 1 year and as very late if > 1 year. Abbreviations: EE-BRS = everolimus-eluting bioresorbable scaffolds, EES = everolimus-eluting stents, PY = patient years, KM = Kaplan-Meier, CI = confidence interval, TLF = target lesion failure, TV-MI = target vessel myocardial infarction, TLR = target lesion revascularization, MACE = major adverse cardiac events, MI = myocardial infarction, TVR = target vessel revascularization, ST = device thrombosis.
Table 4

Multivariate Cox regression models for target lesion failure and major adverse cardiac events

| A. Variable for outcome TLF | Hazard ratio | 95% CI     | p-value |
|---------------------------|--------------|------------|---------|
| Age at device implantation| 1.03         | 0.99–1.06  | 0.12    |
| Insulin-treated diabetes  | 1.82         | 0.97–3.41  | 0.06    |
| Number of treated vessels | 1.17         | 0.47–2.91  | 0.74    |
| Total treated length      | 1.00         | 0.99–1.02  | 0.84    |
| EE-BRS vs. EES            | 1.48         | 0.77–2.87  | 0.24    |

| B. Variable for outcome MACE | Hazard ratio | 95% CI     | p-value |
|-----------------------------|--------------|------------|---------|
| Age at device implantation  | 1.03         | 1.00–1.05  | 0.06    |
| Insulin-treated diabetes    | 1.40         | 0.82–2.37  | 0.22    |
| Number of treated vessels   | 1.57         | 0.77–3.22  | 0.22    |
| Total treated length        | 1.00         | 0.99–1.01  | 0.88    |
| EE-BRS vs. EES              | 1.23         | 0.70–2.17  | 0.47    |

Section A. Multivariate Cox regression model for target lesion failure adjusted for age, insulin-treated diabetes, number of treated vessels, total treated length and destined treatment group. Section B. The same model calculated for major adverse cardiac events. Risk factors are given in hazard ratios with 95% confidence intervals with corresponding p-values. A p-value < 0.05 was considered as statistically significant. No significant differences between both everolimus-eluting bioresorbable scaffolds and everolimus-eluting stents treatment groups were ascertained. Insulin-treatment for diabetes was the only variable that showed a trend as predictor for target lesion failure as was age for major adverse cardiac events.

Abbreviations: TLF = target lesion failure, CI = confidence interval, EE-BRS = everolimus-eluting bioresorbable scaffolds, EES = everolimus-eluting stents, MACE = major adverse cardiac events.

In the present analysis, diabetic patients treated with EES showed clinical event rates similar to those of the EES-treated diabetic patients in a pooled analysis of the SPIRIT and COMPARE trials (6). Furthermore, in our patients with diabetes the efficacy and short- and long-term safety of EE-BRS treatment were favorable and comparable to previous studies (21–24). The performance of EE-BRS and EES have been compared in non-exclusive diabetes populations. Despite some promising early results, long-term assessment revealed no advantage for treating ‘all-comers’ with EE-BRS, but revealed a higher incidence of TV-MI and ST, and a greater angiographic late lumen loss (25–29). The findings of these trials suggest a need for refined bioresorbable devices and a modified duration of DAPT (to correspond with scaffold resorption). Yet, it should be considered that in these previous trials operator experience with EE-BRS implantation was limited and that there was no requirement to follow a formal EE-BRS implantation protocol such as the pre-dilatation, sizing, and post-dilatation (PSP) approach, which in other studies improved safety outcomes (30–32). Interestingly, a 3-year landmark analysis of the ABSORB trials
showed a significant improvement in composite safety outcomes beyond the resorption of the EE-BRS (33, 34).

Nevertheless, previous trials did not focus exclusively on diabetic patients. Patients with diabetes represent a high-risk population that theoretically might show particular benefit from being treated with bioresorbable devices. This is because such devices ‘disappear’ over time, which allows for repeated PCI procedures in the same coronary segment without resulting in multiple metallic mesh layers. Furthermore, the EE-BRS does not cause an incessant stimulation of the diabetes-related vascular inflammation, which may be the case in the permanent presence of certain durable polymers. Therefore, it is conceivable that after PCI with EE-BRS long-term results might be more favorable in patients with diabetes (despite short and medium-term results similar to EES).

In our current all-diabetic patient population, treatment with insulin showed an, albeit statistically non-significant, trend towards prediction of TLF. Such relation was observed in the diabetes subgroup analysis of the ABSORB trials and in a pooled analysis of the SPIRIT and COMPARE trials; both analyses found insulin-treatment to be a risk factor for TLF after PCI with either EE-BRS or EES (6, 21). The increased event risk in insulin-treated patients may be attributable to the generally longer history of diabetes, during which the diabetes-induced chronic vascular inflammation stimulates the progression of atherosclerosis, alters plaque composition and promotes the development of advanced lesions. It is plausible that the severity and duration of diabetes is related to the risk of cardiovascular complications and it appears reasonable to consider this when choosing a coronary revascularization strategy.

Younger patients with non-insulin-treated diabetes and CAD of limited extent may be the most suitable candidates for treatment with EE-BRS (as an alternative to EES), as they might have the greatest benefit from the bioresorbable nature of the device. Furthermore, younger patients have a lower bleeding risk than elderly patients, which is beneficial considering that a prolonged DAPT regimen may be indicated following PCI with EE-BRS. Nevertheless, further dedicated research is required to assess the usefulness of EE-BRS in younger patients. Most likely, such studies will test novel thinner-strut bioresorbable scaffolds that recently became available for research purposes and these studies should include a long-term follow-up (35).

**Limitations**

The hypothesis-generating findings of the present post-hoc analysis should be interpreted carefully in the light of several limitations, including the intrinsic limitations of any comparison between multiple patient cohorts from different studies. Yet, all study participants were treated in the same geographical region and they received the same concomitant medication. Although most baseline clinical characteristics were fairly comparable, there were some differences in angiographic lesion characteristics. Hence, a multivariable analysis was performed, striving for adjustment of known confounders. Considering the time required for full resorption of the EE-BRS, this study did not evaluate the phase shortly before scaffold resorption and in most patients of the EE-BRS group clinical follow-up was finished earlier than
Conclusion

In this patient-level pooled analysis of patients with diabetes from 3 prospective clinical trials, EE-BRS showed clinical outcomes that were quite similar to EES. Further prospective research on treating diabetic patients with (novel) bioresorbable scaffolds may be warranted and should include long-term follow-up.

Abbreviations

CABG = coronary artery bypass grafting

CAD = coronary artery disease

CI = confidence interval

DAPT = dual antiplatelet therapy

EE-BRS = everolimus-eluting bioresorbable scaffolds

EES = everolimus-eluting stents

HR = hazard ratio

MACE = major adverse cardiac events

MI = myocardial infarction

PCI = percutaneous coronary intervention

PSP = pre-dilatation, sizing, and post-dilatation

PY = patient years

ST = device thrombosis

TLF = target lesion failure

TLR = target lesion revascularization

TV-MI = target vessel myocardial infarction

TVR = target vessel revascularization
Declarations

Ethics approval and consent to participate: The ABSORB DM Benelux Study (NTR5447) was performed in concurrence with the Declaration of Helsinki and was registered at the Netherlands Trial Register (NTR) acknowledged by the World Health Organization (WHO) and International Committee of Medical Journal Editors (ICMJE). The TWENTE (NTR1256/NCT01066650) and DUTCH PEERS (NTR2413/NCT01331707) trials were both conducted in concurrence with the Declaration of Helsinki and were registered at the NTR as well as at ClinicalTrials.gov. An approval for ethical committees was sought in all participating centers and countries. The clinical investigations did not test any non-approved device. The ABSORB BVS and the ABSORB GT1 are CE marked products and were used widely in daily clinical practice all over the world from 2009 to 2017. The Xience V EES is widely utilized since 2007 and the platinum-chromium-based EES since 2010. These clinical trials do not involve a medicinal product and are therefore not subject to The European Clinical Trials Directive (2001/20/EC).

Consent for publication: Not applicable.

Availability of data and materials: The dataset used and/or analyzed in the current manuscript was pooled from 3 individual clinical trials. Consequently, the authors of this manuscript do not own the underlying patient-level data. Upon reasonable request, data may be available from the respective organizing centers, but not without formal permission of the principal investigators and the steering committees of each of the separate trials. Corresponding author for any data request is E. Kedhi, the senior corresponding author of this manuscript.

Competing interests: E.H. Ploumen and C. von Birgelen indicated that the research department of Thoraxcentrum Twente has received institutional research grants from Abbott Vascular, Biotronik, Boston Scientific and Medtronic. The other authors declare that they have no competing interests.

Funding: Department of Cardiology, Isala Hospital, Zwolle. Unrestricted research grant from Abbott Vascular and Boston Scientific.

Authors’ contribution: This manuscript is an original work and it is not under consideration for publication elsewhere. E. Kedhi and T.M. Hommels designed the study, co-drafted the manuscript and gave final approval, T.M. Hommels performed statistical analysis, R.S. Hermanides, B. Berta, E. Fabris, G. De Luca, E.H. Ploumen and C. von Birgelen critically revised the manuscript for intellectual content.

Acknowledgements: The study team is grateful to P.C. Koopmans, statistician and epidemiologist from Signidat, Groningen, The Netherlands, for contributing to the statistical analysis of this trial.

References

1. Ritsinger V, Saleh N, Lagerqvist B, Norhammer A. High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and
angioplasty registry. Circ Cardiovasc Interv. 2015;8:e002328.

2. Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation. 2004;109:2727-31.

3. Van Belle E, Périé M, Braune D, et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol. 2002;40:410-7.

4. Grube E, Chevalier B, Guagliumi G, et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J.2012;163:867-75.

5. Jensen LO, Maeng M, Thayssen P, et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109:629-35.

6. Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124:893-900.

7. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004;44:2293-300.

8. Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv. 2010;3:468-75.

9. Otsaka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211-23.

10. Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:e002230.

11. Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. 2016;134:168-82.

12. Tenekecioglu E, Farooq V, Bourantes CV, et al. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovasc Disord. 2016;16:38.

13. Hommels TM, Hermanides RS, Rasoul S, et al. The 1-year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study. Neth Heart J. 2019;27:541-9.

14. Hommels TM, Hermanides RS, Rasoul S, et al. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study. Cardiovasc Diabetol. 2019;18:25.

15. von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59:1350-61.
16. von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383:413-23.

17. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.

18. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010;5:871-4.

19. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581-98.

20. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Nucl Cardiol. 2015;22:1041-4.

21. Kereiakes DJ, Ellis SG, Kimura T, et al. Efficacy and safety of the Absorb everolimus-eluting bioresorbable scaffold for treatment of patients with diabetes mellitus: results of the Absorb diabetic substudy. JACC Cardiovasc Interv. 2017;10:42-9.

22. Tang XF, Ma YL, Song Y, et al. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study. Cardiovasc Diabetol. 2018;17:114.

23. Campos CM, Caixeta A, Franken M, et al. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials. Catheter Cardiovasc Interv. 2018;91:387-95.

24. Anadol R, Schnitzler K, Lorenz L, et al. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds. BMC Cardiovasc Disord. 2018;18:92.

25. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43-54.

26. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905-15.

27. Kereiakes DJ, Ellis SG, Metzger C, et al. 3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. J Am Coll Cardiol. 2017;70:2852-62.

28. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479-91.
29. Tijssen RYG, Kraak RP, Hofma SH, et al. Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. 2018;14:e426-33.

30. Ortega-Paz L, Capodanno D, Gori T, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. 2017;12:2110-7.

31. Stone GW, Abizaid A, Onuma Y, et al. Effect of technique on outcomes following bioresorbable vascular scaffold implantation: analysis from the ABSORB trials. J Am Coll Cardiol. 2017;70:2863-74.

32. Caixeta A, Campos CM, Felix C, et al. Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries. EuroIntervention. 2019;15:623-30.

33. Chevalier B, Cequier A, Dudek D, et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II trial). EuroIntervention. 2018;13:1561-64.

34. Goel S, Pasam RT, Chava S, et al. Three to four years outcomes of the Absorb bioresorbable vascular scaffold versus second-generation drug-eluting stent: a meta-analysis. Catheter Cardiovasc Interv. 2020;95:216-23.

35. Seth A, Onuma Y, Chandra P, et al. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. EuroIntervention. 2019;15:607-14.

Figures
**Graph A**

TLF free survival

- **EE-BRS**
- **EES**

HR = 1.31 (CI 95% 0.69-2.49), p = 0.40
Adjusted HR = 1.48 (CI 95% 0.77-2.87), p = 0.24

**Graph B**

MACE free survival

- **EE-BRS**
- **EES**

HR = 1.09 (CI 95% 0.63-1.89), p = 0.75
Adjusted HR = 1.23 (CI 95% 0.70-2.17), p = 0.47
Figure 1

Shown are the Kaplan-Meier curves with 95% confidence intervals in function of A) target lesion failure free survival and B) major adverse cardiac events free survival at 2-year follow-up. A log-rank test did not prove significant differences between both treatment groups. In a Cox regression model with adjustment for age, insulin-treated diabetes, number of treated vessels and total treated length, treatment with everolimus-eluting bioresorbable scaffolds could not be identified as significant risk factor for both target lesion failure and major adverse cardiac events. Abbreviations: TLF = target lesion failure, EE-BRS = everolimus-eluting bioresorbable scaffolds, EES = everolimus-eluting stents, HR = hazard ratio, CI = confidence interval, MACE = major adverse cardiac events.
7.2 (CI 95% 4.1-11.7)  
5.2 (CI 95% 3.3-7.7)

TLF rate/100 patient years

EE-BRS  
EES

9.1 (CI 95% 5.6-14.1)  
8.3 (CI 95% 5.9-11.4)

MACE rate/100 patient years

EE-BRS  
EES
Figure 2

Shown are the event rates per 100 patient years for the composite endpoints A) target lesion failure and B) major adverse cardiac events for both treatment groups (red and blue bars). In addition, the 95% confidence intervals are also presented (red and blue brackets). No significant differences were found between both treatment groups. Abbreviations: TLF = target lesion failure, CI = confidence interval, EE-BRS = everolimus-eluting bioresorbable scaffolds, EES = everolimus-eluting stents, MACE = major adverse cardiac events.